https://ir.rezolutebio.com/news/rss en-us https://d1io3yog0oux5.cloudfront.net/_ccfa9d9a38d9c21c9cf5ba58fc58a234/rezolutebio/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.rezolutebio.com/news/detail/374/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting Tue, 21 Apr 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/374/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting Tue, 24 Mar 26 07:00:00 -0400 https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference Wed, 04 Mar 26 07:00:00 -0500 https://ir.rezolutebio.com/news/detail/372/rezolute-to-participate-in-the-citizens-life-sciences-conference https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update Thu, 12 Feb 26 16:05:00 -0500 https://ir.rezolutebio.com/news/detail/371/rezolute-reports-second-quarter-fiscal-2026-financial-results-and-provides-business-update https://ir.rezolutebio.com/news/detail/370/rezolute-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026 Wed, 04 Feb 26 07:00:00 -0500 https://ir.rezolutebio.com/news/detail/370/rezolute-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026 https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism Wed, 07 Jan 26 07:00:00 -0500 https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism Thu, 11 Dec 25 07:00:00 -0500 https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism https://ir.rezolutebio.com/news/detail/367/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 Mon, 10 Nov 25 17:30:00 -0500 https://ir.rezolutebio.com/news/detail/367/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 https://ir.rezolutebio.com/news/detail/366/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update Thu, 06 Nov 25 16:05:00 -0500 https://ir.rezolutebio.com/news/detail/366/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update https://ir.rezolutebio.com/news/detail/365/rezolute-to-host-virtual-investor-event-on-ersodetug-development-program Wed, 05 Nov 25 07:30:00 -0500 https://ir.rezolutebio.com/news/detail/365/rezolute-to-host-virtual-investor-event-on-ersodetug-development-program